Financial Results: Page 4

Abbott CEO expects high single-digit sales growth excluding COVID-19 revenues in 2023

By Leo O'Connor

The firm booked diagnostics segment revenues of $3.31 billion in the fourth quarter, down 26.1% year over year. Nonetheless, its CEO sees some easing of macroenvironment challenges that impacted growth in 2022.

January 25, 2023

After Illumina presentation highlighting Grail potential comes a possible EU fine

By Leo O'Connor

At the J.P. Morgan healthcare event this week, Illumina's CEO said Grail must be operated separately and independently pursuant to measures required by the EU.

January 12, 2023

Exact Sciences preliminary Q4 revenues rise 16% on strong screening sales

By LabPulse.com staff writers

The firm expects screening revenue of $401.8 million to $402.8 million, an increase of 45% year-over-year. The screening business includes laboratory service revenue from Cologuard tests.

January 9, 2023

QuidelOrtho expects Q4 revenues between $853 million and $868 million

By LabPulse.com staff writers

Its CEO said QuidelOrtho's strong positioning in the point-of-care market enabled it to serve patients in a strong respiratory season, which drove substantial revenue growth.

January 6, 2023

Hologic Q1 preliminary revenues drop 27% on COVID decline, beat guidance and analyst estimates

By LabPulse.com staff writers

The preliminary revenues are higher than the firm’s recent guidance of $940 million to $990 million and exceed analysts’ average estimate of $966.4 million.

January 9, 2023

Molecular diagnostic firm Biocept to reduce staff by about 35% in restructuring

By LabPulse.com staff writers

The San Diego-based company is implementing a restructuring plan that includes reducing staff in connection with the evaluation of strategic alternatives.

January 6, 2023

Meridian Bioscience Q4 revenues drop 14% on lower COVID-19 testing, misses analysts' estimates

By LabPulse.com staff writers

Diagnostics segment revenue growth was driven by nonmolecular assay products, which increased 22%.

November 22, 2022

Agilent Technologies Q4 revenues rise 11%

By LabPulse.com staff writers

The Diagnostics and Genomics Group generated fourth-quarter revenue of $352 million, up 3% year-over-year.

November 21, 2022

Twist Bioscience Q4 revenues rise 51%

By LabPulse.com staff writers

Among its recent business highlights, the firm noted that it collaborated with PacBio to develop an initial portfolio of off-the-shelf long-read gene panels, including a 50-gene pharmacogenomics panel.

November 18, 2022

Siemens Healthineers Q4 Dx revenues rise 13% on increased sales of COVID-19 rapid antigen tests

By Leo O'Connor

In the recently completed quarter, Siemens Healthineers booked €232 million from COVID-19 rapid antigen tests compared to around €160 million in Q4 2021.

November 9, 2022

Qiagen Q3 net sales decline 7% on COVID challenges, but full-year outlook improves

By LabPulse.com staff writers

Sales of non-COVID-19 products increased 11% year over year to $417 million, while sales of COVID-19 products fell 48% year over year to $83 million.

November 8, 2022

PerkinElmer Q3 revenues down 14% on diagnostics decline

By LabPulse.com staff writers

Discover and Analytical Solutions segment revenues of $312.8 million were up 51% compared year-over-year but, Q3 Diagnostics segment revenues of $399 million declined 39% year-over-year.

November 8, 2022

Previous Page

Page 4 of 12

Next Page